The thing that turns investors heads are themes that have major societal focus. I initially invested in Cytodyn Spring 2020 when the world was focused on an answer to COVID19…as the refrigerator trucks piled up with bodies and there was a scramble to stop the grim reaper it became clear to me Leronlimab could get that job done. That remains true but there is now a shift in focus…the burden from long COVID remains. Mentions of IL6, CRP etc in that journal commentary …with a phase 2 done and dusted it just seems like the focus on long COVID should ultimately shine a light on Leronlimab. The little mab that not only could, but did. C’mon NIH!